Literature DB >> 6653638

Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.

W Krause, J Karras, W Seifert.   

Abstract

Five healthy male volunteers received canrenoate-K 200 mg (Sincomen pro injectione) by intravenous injection and one week later spironolactone 200 mg (Sincomen-100) orally. Plasma levels and urinary excretion of unchanged canrenone were determined up to 24 h by a specific HPLC method. Following intravenous administration, the maximum plasma level of 2066 +/- 876 ng/ml was found after 29 +/- 15 min and thereafter the concentration declined with a half-life of 3.7 +/- 1.2 h. Total clearance was 4.2 +/- 1.7 ml/min . kg. After oral ingestion, the maximum concentration of 177 +/- 33 ng/ml was observed at 4.4 +/- 0.9 h. The absolute bioavailability of canrenone was 25 +/- 9%. Within 24 h, respectively 0.4 and 0.6 mg, canrenone were excreted by the kidney after intravenous and oral administration. The half-life of elimination was 4.9 +/- 1.8 h (i.v.) and 3.9 +/- 1.2 h (p.o.).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653638     DOI: 10.1007/BF00542109

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Antagonism of fludrocortisone by spironolactone and canrenone.

Authors:  G J Huston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

2.  Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.

Authors:  C G Dahlöf; P Lundborg; B A Persson; C G Regårdh
Journal:  Drug Metab Dispos       Date:  1979 Mar-Apr       Impact factor: 3.922

3.  Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.

Authors:  A Karim; J Hribar; W Aksamit; M Doherty; L J Chinn
Journal:  Drug Metab Dispos       Date:  1975 Nov-Dec       Impact factor: 3.922

4.  Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Authors:  W Sadée; M Dagcioglu; R Schröder
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

5.  Pharmacokinetic and metabolic fate of potassium canrenoate (SC-14266) in man.

Authors:  A Karim; R E Ranney; H I Maibach
Journal:  J Pharm Sci       Date:  1971-05       Impact factor: 3.534

6.  Pharmacokinetics of spironolactone in man.

Authors:  U Abshagen; H Rennekamp; G Luszpinski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-12       Impact factor: 3.000

7.  Spironolactone. I. Disposition and metabolism.

Authors:  A Karim; J Zagarella; J Hribar; M Dooley
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

8.  Spironolactone and canrenoate-K: relative potency at steady state.

Authors:  L Ramsay; M Asbury; J Shelton; I Harrison
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

  8 in total
  9 in total

1.  Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.

Authors:  Maysa Suyagh; Ahmed F Hawwa; Paul S Collier; Jeffrey S Millership; Prashant Kole; Muriel Millar; Mike D Shields; Henry L Halliday; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.

Authors:  Amitava Dasgupta; Myrtle J Johnson; Tamal K Sengupta
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

3.  Effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure (IAP) in pigs.

Authors:  F F Gudmundsson; A Viste; O L Myking; K Grong; K Svanes
Journal:  Surg Endosc       Date:  2004-08-26       Impact factor: 4.584

4.  A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.

Authors:  Amitava Dasgupta; Edward Kang; Pradip Datta
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

5.  Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.

Authors:  Amitava Dasgupta; Myrtle J Johnson
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

6.  Improved bioavailability from a spironolactone beta-cyclodextrin complex.

Authors:  N T Yusuff; P York; H Chrystyn; P N Bramley; R D Swallow; B R Tuladhar; M S Losowsky
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.

Authors:  Amitava Dasgupta; Helene Saffer; Alice Wells; Pradip Datta
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

8.  Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.

Authors:  Simon de Denus; Grégoire Leclair; Marie-Pierre Dubé; Isabelle St-Jean; Yassamin Feroz Zada; Essaïd Oussaïd; Martin Jutras; Michael M Givertz; Robert J Mentz; W H Wilson Tang; João Pedro Ferreira; Jean Rouleau; Javed Butler; Andreas P Kalogeropoulos
Journal:  Eur J Heart Fail       Date:  2020-04-01       Impact factor: 15.534

9.  SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.

Authors:  Elodie Bousquet; Talal Beydoun; Pierre-Raphaël Rothschild; Ciara Bergin; Min Zhao; Rui Batista; Marie-Laure Brandely; Benedicte Couraud; Nicolette Farman; Alain Gaudric; François Chast; Francine Behar-Cohen
Journal:  Retina       Date:  2015-12       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.